Global Tier-1 YFORE Introduces Mass-Produced Anti-Pinch Sensors

Global Tier-1 YFORE Introduces Mass-Produced Anti-Pinch Sensors

SUWANEE, Ga., Aug. 31, 2026 /PRNewswire/ -- Global Tier-1 supplier YFORE Technology officially commissioned its Suwanee, Georgia facility, showcasing its market-validated Anti-Pinch Sensor solutions. Leveraging near-shore manufacturing, YFORE...

4‑Year Running: Anti-Cheat Expert (ACE) Appears at Gamescom, Partnering with European Game Studios

4‑Year Running: Anti-Cheat Expert (ACE) Appears at Gamescom, Partnering with European Game Studios

COLOGNE, Germany, Aug. 28, 2026 /PRNewswire/ -- Anti-Cheat Expert (ACE) returned to Gamescom for the fourth consecutive year, presenting a full-lifecycle security framework for complex game operations. During the event, ACE and Tencent Cloud signed...

Manulife Selected for Regulators' First Cohort of GenA.I. Sandbox++ to Advance Customer Experience, Anti-Fraud and Risk Management

Manulife Selected for Regulators' First Cohort of GenA.I. Sandbox++ to Advance Customer Experience, Anti-Fraud and Risk Management

HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Manulife Hong Kong today announced that it has been selected to participate in the First Cohort of the GenA.I. Sandbox++ ("GenA.I. Sandbox++"), a cross-sector initiative led by the Hong Kong Monetary...

Hitek Announces Entry into Share Purchase Agreement to Acquire an Advertising and Digital Marketing Company

Hitek Announces Entry into Share Purchase Agreement to Acquire an Advertising and Digital Marketing Company

XIAMEN, China, August 3, 2026 /PRNewswire/ -- Hitek Global Inc. (Nasdaq: HKIT) (the "Company" or "Hitek"), an information technology consulting and solutions provider, today announced that, on August 3, 2026, it entered into a Share Purchase...

Nippon Paint China Debuts at ARCHIDEX 2026, Showcasing Industrial Innovations

Nippon Paint China Debuts at ARCHIDEX 2026, Showcasing Industrial Innovations

KUALA LUMPUR, Malaysia, July 31, 2026 /PRNewswire/ -- Nippon Paint China made its debut at ARCHIDEX 2026, held from July 29 to August 1 at the Malaysia International Trade and Exhibition Centre in Kuala Lumpur. Invited to exhibit in the China...

Hitek Announces 1-for-25 Reverse Split

Hitek Announces 1-for-25 Reverse Split

XIAMEN, China, July 1, 2026 /PRNewswire/ -- Hitek Global Inc. (Nasdaq: HKIT) (the "Company"), an information technology consulting and solutions provider, announced today that it will effect a reverse split (the "Reverse Split") at a ratio of...

Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio

Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio

HONG KONG, June 12, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for...

Tencent Rolls Out New AI Tools and Enterprise Solutions for Global Markets at Inaugural Tencent Cloud Day Hong Kong

Tencent Rolls Out New AI Tools and Enterprise Solutions for Global Markets at Inaugural Tencent Cloud Day Hong Kong

Productivity agent WorkBuddy, creative agent Miora and Model-as-a-Service platform TokenHub launch globally to accelerate enterprise AI adoption HONG KONG, May 29, 2026 /PRNewswire/ -- Tencent Cloud, the cloud business of global leading technology...

Hitek Announces 1-for-3 Reverse Split

Hitek Announces 1-for-3 Reverse Split

XIAMEN, China, May 27, 2026 /PRNewswire/ -- Hitek Global Inc. (Nasdaq: HKIT) (the "Company"), an information technology consulting and solutions provider, announced today that it will effect a reverse split (the "Reverse Split") at a ratio of...

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026

HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be...

  • 1
  • 2
  • 3
  • 4
  • menu
    menu